{"publication_id":"ea8f0afd-dc89-418d-b158-6e496c6cfe3b","traces":[{"claim_id":"claim_1","claim":"Across retrieved fact-level receipts for dapagliflozin, which endpoints show directionally favorable versus null/non-convergent signals, and what matched PICO remains untested?","candidate_sources":[{"study":"Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF","doi":"10.1161/circulationaha.122.060511","url":"https://doi.org/10.1161/circulationaha.122.060511"},{"study":"Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER","doi":"10.1038/s41591-022-01971-4","url":"https://doi.org/10.1038/s41591-022-01971-4"},{"study":"Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction","doi":"10.1161/circulationaha.120.050391","url":"https://doi.org/10.1161/circulationaha.120.050391"},{"study":"Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF","doi":"10.1002/ejhf.1978","url":"https://doi.org/10.1002/ejhf.1978"},{"study":"Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology","doi":"10.1038/s42255-023-00943-3","url":"https://doi.org/10.1038/s42255-023-00943-3"}]},{"claim_id":"claim_2","claim":"Finding: Dapagliflozin reduced the risk of death from cardiovascular causes (hazard ratio (HR) 0.86, 95% confidence interval (CI) 0.76-0.97; P = 0.01)","candidate_sources":[{"study":"Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF","doi":"10.1161/circulationaha.122.060511","url":"https://doi.org/10.1161/circulationaha.122.060511"},{"study":"Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER","doi":"10.1038/s41591-022-01971-4","url":"https://doi.org/10.1038/s41591-022-01971-4"},{"study":"Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction","doi":"10.1161/circulationaha.120.050391","url":"https://doi.org/10.1161/circulationaha.120.050391"},{"study":"Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF","doi":"10.1002/ejhf.1978","url":"https://doi.org/10.1002/ejhf.1978"},{"study":"Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology","doi":"10.1038/s42255-023-00943-3","url":"https://doi.org/10.1038/s42255-023-00943-3"}]},{"claim_id":"claim_3","claim":"This receipt-backed scoping note has one bounded signal: dapagliflozin shows context-dependent, not uniformly convergent associations across this 5-source primary/review bundle (2020-2024). Grouped by direction, directionally favorable: 3 receipt(s) | comparator/not favorable: 1 receipt(s) | economic/context only: 1 receipt(s). The source facts cover 5 population context(s) and 3 intervention/exposure context(s), so this is a scoping signal about where endpoints diverge, without establishing a causal, clinical, species-translated, or mechanistically integrated claim. The listed effect sizes remain source-specific across endpoints and populations; they are not pooled or averaged. Concrete source-level examples: hazard ratio, 0.74 [95% CI, 0.58–0.92]; Dapagliflozin reduced the risk of death from cardiovascular causes (hazard ratio (HR) 0.86, 95% confidence interval (CI) 0.76-0.97; P = 0.01); The hazard ratio (95% CI) for the primary end point in patients with chronic kidney disease was 0.71 (0.59–0.86).","candidate_sources":[{"study":"Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF","doi":"10.1161/circulationaha.122.060511","url":"https://doi.org/10.1161/circulationaha.122.060511"},{"study":"Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER","doi":"10.1038/s41591-022-01971-4","url":"https://doi.org/10.1038/s41591-022-01971-4"},{"study":"Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction","doi":"10.1161/circulationaha.120.050391","url":"https://doi.org/10.1161/circulationaha.120.050391"},{"study":"Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF","doi":"10.1002/ejhf.1978","url":"https://doi.org/10.1002/ejhf.1978"},{"study":"Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology","doi":"10.1038/s42255-023-00943-3","url":"https://doi.org/10.1038/s42255-023-00943-3"}]},{"claim_id":"claim_4","claim":"null/non-convergent or other/mixed: the extracted fact is null, mixed, or not directionally interpretable.","candidate_sources":[{"study":"Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF","doi":"10.1161/circulationaha.122.060511","url":"https://doi.org/10.1161/circulationaha.122.060511"},{"study":"Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER","doi":"10.1038/s41591-022-01971-4","url":"https://doi.org/10.1038/s41591-022-01971-4"},{"study":"Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction","doi":"10.1161/circulationaha.120.050391","url":"https://doi.org/10.1161/circulationaha.120.050391"},{"study":"Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF","doi":"10.1002/ejhf.1978","url":"https://doi.org/10.1002/ejhf.1978"},{"study":"Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology","doi":"10.1038/s42255-023-00943-3","url":"https://doi.org/10.1038/s42255-023-00943-3"}]},{"claim_id":"claim_5","claim":"directionally favorable: Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER — Dapagliflozin reduced the risk of death from cardiovascular causes (hazard ratio (HR) 0.86, 95% confidence interval (CI) 0.76-0.97; P = 0.01)","candidate_sources":[{"study":"Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF","doi":"10.1161/circulationaha.122.060511","url":"https://doi.org/10.1161/circulationaha.122.060511"},{"study":"Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER","doi":"10.1038/s41591-022-01971-4","url":"https://doi.org/10.1038/s41591-022-01971-4"},{"study":"Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction","doi":"10.1161/circulationaha.120.050391","url":"https://doi.org/10.1161/circulationaha.120.050391"},{"study":"Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF","doi":"10.1002/ejhf.1978","url":"https://doi.org/10.1002/ejhf.1978"},{"study":"Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology","doi":"10.1038/s42255-023-00943-3","url":"https://doi.org/10.1038/s42255-023-00943-3"}]},{"claim_id":"claim_6","claim":"Specific moderators in this bundle are population/indication (iron-deficient patients with heart failure; patients with heart failure; patients with heart failure with reduced ejection fraction; patients with heart failure with reduced ejection fraction and chronic kidney disease (eGFR <60 mL/min/1.73m²); patients with type 2 diabetes with features of SIDD or SIRD), study design/evidence type (primary/review). Single primary-study estimates are separated from pooled review or meta-analytic estimates rather than treated as interchangeable.","candidate_sources":[{"study":"Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF","doi":"10.1161/circulationaha.122.060511","url":"https://doi.org/10.1161/circulationaha.122.060511"},{"study":"Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER","doi":"10.1038/s41591-022-01971-4","url":"https://doi.org/10.1038/s41591-022-01971-4"},{"study":"Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction","doi":"10.1161/circulationaha.120.050391","url":"https://doi.org/10.1161/circulationaha.120.050391"},{"study":"Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF","doi":"10.1002/ejhf.1978","url":"https://doi.org/10.1002/ejhf.1978"},{"study":"Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology","doi":"10.1038/s42255-023-00943-3","url":"https://doi.org/10.1038/s42255-023-00943-3"}]},{"claim_id":"claim_7","claim":"The selected receipts group because each carries a fact-level extraction for dapagliflozin; they separate by context (human clinical/observational) and endpoint, so they are not interchangeable evidence for one pooled claim.","candidate_sources":[{"study":"Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF","doi":"10.1161/circulationaha.122.060511","url":"https://doi.org/10.1161/circulationaha.122.060511"},{"study":"Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER","doi":"10.1038/s41591-022-01971-4","url":"https://doi.org/10.1038/s41591-022-01971-4"},{"study":"Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction","doi":"10.1161/circulationaha.120.050391","url":"https://doi.org/10.1161/circulationaha.120.050391"},{"study":"Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF","doi":"10.1002/ejhf.1978","url":"https://doi.org/10.1002/ejhf.1978"},{"study":"Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology","doi":"10.1038/s42255-023-00943-3","url":"https://doi.org/10.1038/s42255-023-00943-3"}]},{"claim_id":"claim_8","claim":"The signal is purely descriptive of effect-direction heterogeneity; it cannot support even a weak causal or comparative-efficacy inference, and pooling across these PICOs would be inappropriate.","candidate_sources":[{"study":"Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF","doi":"10.1161/circulationaha.122.060511","url":"https://doi.org/10.1161/circulationaha.122.060511"},{"study":"Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER","doi":"10.1038/s41591-022-01971-4","url":"https://doi.org/10.1038/s41591-022-01971-4"},{"study":"Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction","doi":"10.1161/circulationaha.120.050391","url":"https://doi.org/10.1161/circulationaha.120.050391"},{"study":"Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF","doi":"10.1002/ejhf.1978","url":"https://doi.org/10.1002/ejhf.1978"},{"study":"Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology","doi":"10.1038/s42255-023-00943-3","url":"https://doi.org/10.1038/s42255-023-00943-3"}]}]}